AI-generated voice clones are bringing back the voices of people with MND, allowing some to communicate, connect, and even ...

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Neighborhood disadvantage, or living in a poorer region, was linked to significantly shorter survival time for ALS patients ...

Shares of Voyager Therapeutics (NASDAQ:VYGR) plummeted 20% as the company announced a shift in its gene therapy program for ...

New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology firm focused on neurogenetic medicines with a market capitalization of $290 million, announced today it is reassessing its ...

Voyager Therapeutics said it will assess alternate payloads related to its gene therapeutic program related to a form of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

Voyager Therapeutics (VYGR) has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 amyotrophic ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...

A trial that will test a noninvasive device called MyoRegulator as a treatment for ALS was cleared to start enrolling ...